Comprehensive real-world review of GLP-1 weight loss drugs confirms efficacy but highlights adherence and equity challenges | Research

The takeaway

Narrative review of real-world GLP-1 drug use for obesity confirms meaningful weight loss but reveals challenges including lower-than-trial efficacy, adherence issues, drug shortages, cost barriers, and demographic prescribing disparities.

Real-world gap identified
GLP-1 drugs work in real life but underperform trials due to adherence, cost, shortages, and access disparities—systemic solutions needed for population-level impact

What the researchers found

Real-world: meaningful weight loss but below trial efficacy. Barriers: adherence, drug shortages, cost, insurance coverage. Disparities: socioeconomic, racial/ethnic in prescribing. AEs: consistent with trials (GI predominant). Need: systemic solutions for sustained access.

Why it matters

Understanding the gap between trial and real-world GLP-1 drug performance—and the barriers causing it—is essential for public health planning as these drugs scale to millions of users.

How the study worked

Narrative review of published real-world GLP-1RA evidence for obesity.

What this study cannot tell us

Narrative review. Real-world evidence is heterogeneous. Most data from Western countries. Rapidly evolving landscape.

How to read the evidence

Comprehensive narrative review of real-world evidence.

When this study was published

Published in 2025.

The bigger picture

The GLP-1 revolution's real-world impact depends on solving access, adherence, and equity challenges. Without addressing these, the benefit will remain limited to privileged populations.

Questions still open

How can drug shortages be prevented?
What policies would improve equity in GLP-1 access?
Would digital health tools improve real-world adherence?

Common questions

Do GLP-1 drugs work as well in real life as in clinical trials?

They work, but typically not quite as well. Real-world weight loss tends to be lower than clinical trial results because of adherence challenges, drug shortages, cost barriers, and less intensive monitoring. However, clinically meaningful weight loss is still consistently achieved.

Why can not everyone access GLP-1 drugs?

Several barriers exist: high drug costs, limited insurance coverage, drug supply shortages, and demographic disparities in prescribing. This review highlights that socioeconomic and racial/ethnic factors affect who gets prescribed these drugs, creating an equity problem that undermines their public health potential.

Read the original research

Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.

Diabetes, obesity & metabolism, 27 Suppl 2(Suppl 2), 66-88

View on PubMed ↗Publisher’s paper ↗

Citation

Thomsen, Reimar W; Mailhac, Aurélie; Løhde, Julie B; Pottegård, Anton. (2025). Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.. Diabetes, obesity & metabolism, 27 Suppl 2(Suppl 2), 66-88. https://doi.org/10.1111/dom.16364